Skip to main content
Log in

Cost of Illness in Adult Patients with Hypopituitarism

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To compare the healthcare costs of patients with hypopituitarism with those of individuals from the general population.

Design: Aretrospective study of costs over 1 year. Estimates of direct and indirect health-related costs were calculated for patients from the general population using existing databases, and for patients with hypopituitarism using records of all patients eligible to participate on 31 December 1989 who could be traced, were willing to participate and had not been treated for acromegaly or Cushing’s disease.

Setting: The catchment area of the Endocrine Unit, Sahlgrenska Hospital, Gothenburg. The study was conducted from the societal perspective. Reference data were collected from official regional and national registries.

Patients: 199 patients with adult-onset hypopituitarism in whom replacement therapy was given to maintain the adrenal, thyroid and gonadal (but not the somatotropic) axes.

Main outcome measures and results: Direct and indirect costs incurred by patients with hypopituitarismwere higher than those incurred by individuals from the general population. The total direct costs per patient were Swedish Crowns (SEK)22 920 vs SEK12 080 (p < 0.003) in the general population, and the highest costs were related to inpatient care. Of the patients aged 16 to 64 years, 22% had drawn a disability pension versus the expected 11.3% (p < 0.003) in the general population, and the patients had a mean sick leave of 38.4 days vs 23.5 (p < 0.001). Total excess costs for all patients with hypopituitarism were SEK 35 768 per patient (p < 0.007).

Conclusions: Patients with hypopituitarism incur more health-related costs than individuals from the general population. They also take more sick leave days and are more likely to claim a disability pension than members of the general population. Further cost analyses are needed to determine whether improvements in diagnostic and surgical procedures, and hormone replacement therapy, can reduce the healthcare costs of patients with hypopituitarism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Sönksen PH. Replacement therapy in hypothalamo–pituitary insufficiency after childhood: management in the adult. Horm Res 1990; 33 Suppl. 4: 45–51

    Google Scholar 

  2. Hakkaart-van Roijen L, Beckers A, Stevenaert A, et al. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics 1998; 14: 395–403

    Article  PubMed  CAS  Google Scholar 

  3. Sanmarti A, Lucas A, Hawkins F, et al., Collaborative ODA (Observational GH Deficiency in Adults) Group. Observational study in adult hypopituitary patients with untreated growth hormone deficiency (ODA study): socio-economic impact and health status. Eur J Endocrinol 1999; 141 (5): 481–9

    Article  PubMed  CAS  Google Scholar 

  4. Jönsson B. Diabetes: the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand Suppl 1983; 671: 19–27

    PubMed  Google Scholar 

  5. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96 (1): 102–9

    PubMed  CAS  Google Scholar 

  6. KoopmanschapMA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc SciMed 1992; 34 (9): 1005–10

    Google Scholar 

  7. Gerard K, Donaldson C, Maynard AK. The cost of diabetes. Diabetes Med 1989; 6 (2): 164–70

    Article  CAS  Google Scholar 

  8. An official investigation: needs and resources in healthcare – an analysis [in Swedish]. Stockholm:Ministry of Health and Social Affairs, 1996

  9. The National Social Insurance Board. Disability pensions: cost and number of reimbursed pensioners in December 1989 [in Swedish]. Stockholm: Riksförsäkringsverket

  10. National Bureau of Statistics. Statistical yearbook of Sweden 1998. Stockholm: Official Statistics of Sweden, 1998

    Google Scholar 

  11. Lindgren B. The economic impact of illness. In: Abshagen U, Munnich FE, editors. Cost of illness and benefits of drug treatment. Munich: WZuckschwerdt Verlag, 1990: 12–20

    Google Scholar 

  12. Drummond M. Cost-of-illness studies: a major headache. Pharmacoeconomics 1992; 2 (1): 1–4

    Article  PubMed  CAS  Google Scholar 

  13. Thorner MO, Vance ML, Horvath E, et al. The anterior pituitary. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. 8th ed. Philadelphia (PA): WB Saunders Company, 1992: 221–310

  14. Rosén T, Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285–8

    Article  PubMed  Google Scholar 

  15. Markussis V, Beshyah SA, Fisher C, et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992; 340: 1188–92

    Article  PubMed  CAS  Google Scholar 

  16. Bülow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997; 46: 75–81

    Article  Google Scholar 

  17. Rosén T, Hansson T, Granhed H, et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol 1993; 129: 201–8

    PubMed  Google Scholar 

  18. Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, et al. Increased fracture frequency in adult patients with hypopituitarism. Eur J Endocrinol 1997; 137: 240–5

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Paul Verboom, MSc, is gratefully acknowledged for his support in completing the analyses. The authors are indebted to Pharmacia & Upjohn and the Swedish Medical Research Council (Grant 244115707) for economic support. This article was presented in part at the Annual Meeting of the Endocrine Society, Minneapolis, Minnesota, USA, in June 1997.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ehrnborg, C., Roijen, L.HV., Jonsson, B. et al. Cost of Illness in Adult Patients with Hypopituitarism. Pharmacoeconomics 17, 621–628 (2000). https://doi.org/10.2165/00019053-200017060-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200017060-00008

Keywords

Navigation